{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T18:55:53Z","timestamp":1782586553630,"version":"3.54.5"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117431","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:29:50Z","timestamp":1760743790000},"page":"117431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P4","title":["Glucagon-like peptide-1 agonists alleviate adenine-induced nephrotoxicity in rats: interaction with the renin-angiotensin system and role of NLRP-3 inflammasome, nephrin and KIM-1"],"prefix":"10.1016","volume":"242","author":[{"given":"Hisham A.","family":"Nematalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Elharoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Sheta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar R.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Basta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3004-5675","authenticated-orcid":false,"given":"Ali H.","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed F.","family":"El-Yazbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117431_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10071155","article-title":"Oxidative stress in patients with advanced ckd and renal replacement therapy: the key role of peripheral blood leukocytes","volume":"10","author":"Vida","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.bcp.2025.117431_b0010","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular Disease in Chronic Kidney Disease Pathophysiological Insights and Therapeutic Options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2025.117431_b0015","doi-asserted-by":"crossref","unstructured":"K.R. Tuttle, C.R. Jones, K.B. Daratha, A.K. Koyama, S.B. Nicholas, R.Z. Alicic, O.K. Duru, J.J. Neumiller, K.C. Norris, N. R\u00edos Burrows, M.E. Pavkov, Incidence of Chronic Kidney Disease among Adults with Diabetes, 2015\u20132020, New England Journal of Medicine 387 (2022) 1430\u20131431. doi:10.1056\/nejmc2207018.","DOI":"10.1056\/NEJMc2207018"},{"key":"10.1016\/j.bcp.2025.117431_b0020","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","article-title":"Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease","volume":"18","author":"Matsushita","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.bcp.2025.117431_b0025","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.45421","article-title":"Safety and Efficacy of Liraglutide on Cardiovascular Outcomes in patients with Diabetes Mellitus: a Meta-Analysis of Randomized Controlled Trials","author":"Vemulapalli","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.bcp.2025.117431_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176525","article-title":"Liraglutide and Naringenin relieve depressive symptoms in mice by enhancing Neurogenesis and reducing inflammation","volume":"971","author":"Abdelkawy","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117431_b0035","doi-asserted-by":"crossref","unstructured":"C. Meurot, C. Martin, L. Sudre, J. Breton, C. Bougault, R. Rattenbach, K. Bismuth, C. Jacques, F. Berenbaum, Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis, (123AD). doi:10.1038\/s41598-022-05323-7.","DOI":"10.1038\/s41598-022-05323-7"},{"key":"10.1016\/j.bcp.2025.117431_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113236","article-title":"Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases","volume":"152","author":"Yang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2025.117431_b0045","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.amjmed.2003.09.034","article-title":"The renin-angiotensin-aldosterone system and the kidney: Effects on kidney disease","volume":"116","author":"Brewster","year":"2004","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcp.2025.117431_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10071041","article-title":"The pivotal role of oxidative stress in the pathophysiology of cardiovascular-renal remodeling in kidney disease","volume":"10","author":"Ravarotto","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.bcp.2025.117431_b0055","article-title":"Role of inflammation in the progression of diabetic kidney disease","volume":"8","author":"Chatterjee","year":"2024","journal-title":"Vessel plus"},{"key":"10.1016\/j.bcp.2025.117431_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/cells8111389","article-title":"The role of inflammasome-dependent and inflammasome-independent nlrp3 in the kidney","volume":"8","author":"Kim","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2025.117431_b0065","article-title":"Signaling pathways of chronic kidney diseases, implications for therapeutics","volume":"7","author":"Yuan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2025.117431_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9051463","article-title":"The marker of tubular injury, kidney injury molecule-1 (KIM-1), in acute kidney injury complicating acute pancreatitis: a preliminary study","volume":"9","author":"Wajda","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2025.117431_b0075","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/path.2175","article-title":"Tubular kidney injury molecule-1 (KIM-1) in human renal disease","volume":"212","author":"van Timmeren","year":"2007","journal-title":"J. Pathol."},{"key":"10.1016\/j.bcp.2025.117431_b0080","doi-asserted-by":"crossref","DOI":"10.1186\/2050-7771-2-21","article-title":"Nephrin - a biomarker of early glomerular injury","volume":"2","author":"Kandasamy","year":"2014","journal-title":"Biomark Res"},{"key":"10.1016\/j.bcp.2025.117431_b0085","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","article-title":"ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for patients with Non-Dialysis Chronic Kidney Disease Stages 3\u20135: a Network Meta-Analysis of Randomised Clinical Trials","volume":"80","author":"Zhang","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2025.117431_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1101068","article-title":"Renin\u2013angiotensin\u2013aldosterone pathway modulators in chronic kidney disease: a comparative review","volume":"14","author":"Alshahrani","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117431_b0095","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality among Persons with Low estimated Glomerular Filtration Rate","volume":"180","author":"Qiao","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.bcp.2025.117431_b0100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12651","article-title":"Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial","volume":"18","author":"Skov","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bcp.2025.117431_b0105","doi-asserted-by":"crossref","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like Peptide-1 (GLP-1): effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2025.117431_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2014.00023","article-title":"Tissue renin-angiotensin systems: a unifying hypothesis of metabolic disease","volume":"5","author":"Skov","year":"2014","journal-title":"Front Endocrinol (lausanne)"},{"key":"10.1016\/j.bcp.2025.117431_b0115","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2213-8587(19)30065-8","article-title":"GLP-1 and the renin\u2013angiotensin\u2013aldosterone system","author":"Jim\u00e9nez","year":"2019","journal-title":"Lancet Diabetes Endocrinol 7"},{"key":"10.1016\/j.bcp.2025.117431_b0120","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.nefro.2015.08.004","article-title":"Animal models of pediatric chronic kidney disease. is adenine intake an appropriate model?","volume":"35","author":"Claramunt","year":"2015","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.bcp.2025.117431_b0125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nep.13180","article-title":"Adenine-induced chronic kidney disease in rats","volume":"23","author":"Diwan","year":"2018","journal-title":"Nephrology"},{"key":"10.1016\/j.bcp.2025.117431_b0130","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic Kidney Disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2025.117431_b0135","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-019-1621-6","article-title":"Chronic treatment of curcumin improves hepatic lipid metabolism and alleviates the renal damage in adenine-induced chronic kidney disease in Sprague-Dawley rats","volume":"20","author":"Ghelani","year":"2019","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.bcp.2025.117431_b0140","article-title":"The effect of metformin in diabetic and non-diabetic rats with experimentally-induced chronic kidney disease","volume":"11","author":"M. Al Za\u2019Abi, B.H. Ali, Y. Al Suleimani, S.A. Adham, H. Ali, P. Manoj, M. Ashique, A. Nemmar,","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.bcp.2025.117431_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117415","article-title":"Novel thiazolones for the simultaneous modulation of PPAR\u03b3, COX-2 and 15-LOX to address metabolic disease-associated portal inflammation","volume":"289","author":"El-Shoukrofy","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117431_b0150","series-title":"2024 International Conference on Machine Intelligence and Smart Innovation","first-page":"224","article-title":"A proposed computational workflow for bioinformatics-based drug repurposing: a case study of Canagliflozin","author":"El-Nikhely","year":"2024"},{"key":"10.1016\/j.bcp.2025.117431_b0155","article-title":"The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA\/CREB pathway in a rat model of knee osteoarthritis","volume":"16","author":"Que","year":"2019","journal-title":"Journal of Inflammation (united Kingdom)"},{"key":"10.1016\/j.bcp.2025.117431_b0160","doi-asserted-by":"crossref","unstructured":"N. Guo, J. Sun, H. Chen, H. Zhang, Z. Zhang, D. Cai, Liraglutide prevents diabetes progression in prediabetic OLETF rats Collaborative Analysis of Diagnostic Criteria in Europe, 2013.","DOI":"10.1507\/endocrj.EJ12-0094"},{"key":"10.1016\/j.bcp.2025.117431_b0165","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0008-6363(03)00544-3","article-title":"Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats","volume":"60","author":"Sch\u00e4fer","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2025.117431_b0170","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s13105-022-00937-x","article-title":"Resveratrol ameliorates the behavioural and molecular changes in rats exposed to uninephrectomy: role of hippocampal SIRT1, BDNF and AChE","volume":"79","author":"Basta","year":"2023","journal-title":"J. Physiol. Biochem."},{"key":"10.1016\/j.bcp.2025.117431_b0175","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0076-6879(90)86135-I","article-title":"[43] Malondialdehyde determination as index of lipid Peroxidation","volume":"186","author":"Draper","year":"1990","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.bcp.2025.117431_b0180","doi-asserted-by":"crossref","unstructured":"B. Yang, A. Meguid, E.L. Nahas, G.L. Thomas, J.L. Haylor, P.F. Watson, B. Wagner, T.S. Johnson, Caspase-3 and apoptosis in experimental chronic renal scarring, 2001.","DOI":"10.1046\/j.1523-1755.2001.00013.x"},{"key":"10.1016\/j.bcp.2025.117431_b0185","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.659","article-title":"Protective effect of tolvaptan against cyclophosphamide-induced nephrotoxicity in rat models","author":"El-Shabrawy","year":"2020","journal-title":"Pharmacol Res Perspect 8"},{"key":"10.1016\/j.bcp.2025.117431_b0190","first-page":"1","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2025.117431_b0195","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (lausanne)"},{"key":"10.1016\/j.bcp.2025.117431_b0200","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","article-title":"Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products\u2013induced inflammation","volume":"105","author":"Sourris","year":"2024","journal-title":"Kidney Int."},{"key":"10.1016\/j.bcp.2025.117431_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13098-025-01831-4","article-title":"Impact of GLP-1 receptor agonist-based therapies on cardiovascular and renal outcomes in diabetic and non-diabetic patients with CKD","volume":"17","author":"Siniukovich","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.bcp.2025.117431_b0210","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/8974960","article-title":"Liraglutide Attenuates Hepatic Oxidative stress, Inflammation, and Apoptosis in Streptozotocin-Induced Diabetic mice by Modulating the Wnt\/\u03b2-Catenin Signaling Pathway","volume":"2023","author":"Yu","year":"2023","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.bcp.2025.117431_b0215","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90191-w","article-title":"The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes","volume":"11","author":"Sivalingam","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.117431_b0220","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.neuro.2022.08.007","article-title":"Liraglutide reduces oxidative stress and improves energy metabolism in methylglyoxal-induced SH-SY5Y cells","volume":"92","author":"Qi","year":"2022","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.bcp.2025.117431_b0225","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bbrc.2023.04.012","article-title":"GLP-1 receptor agonist, liraglutide, protects podocytes from apoptosis in diabetic nephropathy by promoting white fat browning","volume":"664","author":"Wang","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2025.117431_b0230","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-016-0159-z","article-title":"Interactions between kidney disease and diabetes: dangerous liaisons","volume":"8","author":"Pecoits-Filho","year":"2016","journal-title":"Diabetol. Metab. Syndr."},{"issue":"36","key":"10.1016\/j.bcp.2025.117431_b0235","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.2174\/0929867328666210222092628","article-title":"Lipid-lowering therapies for atherosclerosis: Statins, fibrates, ezetimibe and pcsk9 monoclonal antibodies","volume":"28","author":"Hajj Ali","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117431_b0240","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/B978-0-12-815876-0.00066-8","article-title":"Dyslipidemia and Chronic Kidney Disease","author":"Reule","year":"2020","journal-title":"Chronic Renal Disease"},{"key":"10.1016\/j.bcp.2025.117431_b0245","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1159\/000518456","article-title":"Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives","volume":"52","author":"Theofilis","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.bcp.2025.117431_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1088015","article-title":"Paradoxical reduction of plasma lipids and atherosclerosis in mice with adenine-induced chronic kidney disease and hypercholesterolemia","volume":"10","author":"Padalkar","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.bcp.2025.117431_b0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125285","article-title":"Ameliorative effect of chrysin on adenine-induced chronic kidney disease in rats","volume":"10","author":"Ali","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.117431_b0260","first-page":"263","article-title":"Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry Effects of the SGLT-2 Inhibitor Canagliflozin on Adenine-Induced Chronic Kidney Disease in Rats","volume":"52","author":"Ali","year":"2019","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.bcp.2025.117431_b0265","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8845607","article-title":"Cardiac Inflammation, Oxidative stress, Nrf2 Expression, and Coagulation events in mice with Experimental Chronic Kidney Disease","volume":"2021","author":"Nemmar","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.bcp.2025.117431_b0270","article-title":"Evidence of kidney injury in preeclampsia: increased maternal and urinary levels of NGAL and KIM-1 and their enhanced expression in proximal tubule epithelial cells","volume":"10","author":"Wang","year":"2023","journal-title":"Front Med (lausanne)"},{"key":"10.1016\/j.bcp.2025.117431_b0275","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.ymthe.2022.08.013","article-title":"KIM-1 augments hypoxia-induced tubulointerstitial inflammation through uptake of small extracellular vesicles by tubular epithelial cells","volume":"31","author":"Chen","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2025.117431_b0280","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000330187","article-title":"Glomerular Expression of Kidney Injury Molecule-1 and Podocytopenia in Diabetic Glomerulopathy","volume":"34","author":"Zhao","year":"2011","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.bcp.2025.117431_b0285","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1172\/JCI45361","article-title":"Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis","volume":"123","author":"Humphreys","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bcp.2025.117431_b0290","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1159\/000458737","article-title":"Kidney Injury Molecule-1 is Elevated in Nephropathy and Mediates Macrophage Activation via the Mapk Signalling Pathway","volume":"41","author":"Tian","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.bcp.2025.117431_b0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198013","article-title":"Nephrin is necessary for podocyte recovery following injury in an adult mature glomerulus","volume":"13","author":"Verma","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.117431_b0300","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1681\/ASN.2014040405","article-title":"Nephrin preserves podocyte viability and glomerular structure and function in adult kidneys","volume":"26","author":"Li","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bcp.2025.117431_b0305","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1681\/ASN.2008111219","article-title":"Nephrin deficiency activates NF-\u03baB and promotes glomerular injury","volume":"20","author":"Hussain","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bcp.2025.117431_b0310","doi-asserted-by":"crossref","unstructured":"G. Remuzzi, N. Perico, M. Macia, P. Ruggenenti, The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease, 2005.","DOI":"10.1111\/j.1523-1755.2005.09911.x"},{"key":"10.1016\/j.bcp.2025.117431_b0315","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.606392","article-title":"Renal Inflammation and Innate Immune Activation Underlie the transition from Gentamicin-Induced Acute Kidney Injury to Renal Fibrosis","volume":"12","author":"Albino","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bcp.2025.117431_b0320","doi-asserted-by":"crossref","DOI":"10.3390\/antiox13121454","article-title":"Oxidative stress in Kidney Injury and Hypertension","volume":"13","author":"Arendshorst","year":"2024","journal-title":"Antioxidants"},{"key":"10.1016\/j.bcp.2025.117431_b0325","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.1992.263.5.E863","article-title":"Reciprocal feedback regulation of kidney angiotensinogen and renin mRNA expressions by angiotensin II","volume":"263","author":"Schunkert","year":"1992","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2025.117431_b0330","doi-asserted-by":"crossref","first-page":"R410","DOI":"10.1152\/ajpregu.00083.2024","article-title":"Liraglutide ameliorates inflammation and fibrosis by downregulating the TLR4\/ MyD88\/NF-jB pathway in diabetic kidney disease","volume":"327","author":"Huang","year":"2024","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.bcp.2025.117431_b0335","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s10787-022-00956-6","article-title":"Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK\/SIRT1 signaling and NLRP3 inflammasome","volume":"30","author":"Ammar","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.bcp.2025.117431_b0340","article-title":"Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in mice by Regulating the Local Renin-Angiotensin System","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117431_b0345","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.809952","article-title":"Dissecting the Crosstalk between Nrf2 and NF-\u03baB Response Pathways in Drug-Induced Toxicity","volume":"9","author":"Gao","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2025.117431_b0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antiox10020258","article-title":"Pharmacotherapy against oxidative stress in chronic kidney disease: Promising small molecule natural products targeting nrf2-ho-1 signaling","volume":"10","author":"Uddin","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.bcp.2025.117431_b0355","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3390\/kidneydial2030034","article-title":"GLP-1 Receptor Agonists in the Treatment of patients with Type 2 Diabetes and Chronic Kidney Disease","volume":"2","author":"Neumiller","year":"2022","journal-title":"Kidney and Dialysis"},{"key":"10.1016\/j.bcp.2025.117431_b0360","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2265.2002.01613.x","article-title":"Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism","volume":"57","author":"Seifarth","year":"2002","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.bcp.2025.117431_b0365","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/HYPERTENSIONAHA.120.14871","article-title":"Effects of Ramipril on the Aldosterone\/Renin Ratio and the Aldosterone\/Angiotensin II Ratio in patients with Primary Aldosteronism","volume":"76","author":"Guo","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2025.117431_b0370","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/01.HYP.0000038478.59760.41","article-title":"Drug effects on aldosterone\/plasma renin activity ratio in primary aldosteronism","volume":"40","author":"Mulatero","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2025.117431_b0375","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2337\/dc14-1958","article-title":"Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes","volume":"38","author":"Lovshin","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bcp.2025.117431_b0380","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.234","article-title":"Activation of the renal GLP-1R leads to expression of Ren1 in the renal vascular tree","volume":"4","author":"Bj\u00f8rnholm","year":"2021","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.bcp.2025.117431_b0385","first-page":"3559","article-title":"Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats","volume":"156","author":"Roman\u00ed-P\u00e9rez","year":"2015","journal-title":"Endocrinology (united States)"},{"key":"10.1016\/j.bcp.2025.117431_b0390","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","article-title":"Angiotensin-converting enzyme 2 and angiotensin 1-7: Novel therapeutic targets","volume":"11","author":"Jiang","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.bcp.2025.117431_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101162","article-title":"Role and Interaction between ACE1, ACE2 and their Related Genes in Cardiovascular Disorders","volume":"48","author":"Bhushan","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.bcp.2025.117431_b0400","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6920620","article-title":"Liraglutide enhances the activity of the Ace-2\/Ang(1-7)\/Mas receptor pathway in lungs of Male pups from food-restricted mothers and prevents the reduction of SP-A","volume":"2018","author":"Fandi\u00f1o","year":"2018","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.bcp.2025.117431_b0405","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1101068","article-title":"Renin\u2013angiotensin\u2013aldosterone pathway modulators in chronic kidney disease: a comparative review","volume":"14","author":"Alshahrani","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117431_b0410","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 Inhibitors in patients with CKD: Expanding Indications and Practical Considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.bcp.2025.117431_b0415","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with Chronic Kidney Disease","volume":"388","author":"T.E.-K.C. Group","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2025.117431_b0420","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2025.117431_b0425","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2025.117431_b0430","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2215\/CJN.01260120","article-title":"Liraglutide for the treatment of type 2 diabetes and safety in diabetic kidney disease liraglutide and diabetic kidney disease","volume":"15","author":"Cherney","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bcp.2025.117431_b0435","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2215\/CJN.11881019","article-title":"Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease","volume":"15","author":"Mann","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bcp.2025.117431_b0440","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10157-020-02007-2","article-title":"Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats","volume":"25","author":"Yamada","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.bcp.2025.117431_b0445","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae296","article-title":"GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity","volume":"17","author":"Abasheva","year":"2024","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.bcp.2025.117431_b0450","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.ekir.2024.04.028","article-title":"Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial","volume":"9","author":"Tuttle","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.bcp.2025.117431_b0455","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol."}],"updated-by":[{"DOI":"10.1016\/j.bcp.2025.117552","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000}}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T01:33:04Z","timestamp":1769477584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225006963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":91,"alternative-id":["S0006295225006963"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117431","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 agonists alleviate adenine-induced nephrotoxicity in rats: interaction with the renin-angiotensin system and role of NLRP-3 inflammasome, nephrin and KIM-1","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117431","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117431"}}